Whitepapers

Whitepaper Jul 8, 2025

Learnings and Advice From the First Two Rounds of Medicare Drug Price Negotiations

Antibody Drug Conjugates

Whitepaper Jun 12, 2025

Antibody Drug Conjugates: From ” Targeted Chemotherapy” to Next Generation Precision Oncology Agents

Whitepaper May 2, 2025

Global to Local: Where Should the Balance Lie?

A doctor and patient facing in the same direction, with a humanoid android figure representing AI between them

Whitepaper Apr 30, 2025

Is AI the Third Person in the Doctor–Patient Relationship?

Whitepaper Mar 24, 2025

Potential Impact of the IRA on the Generic Drug Market

Whitepaper Mar 13, 2025

MASH in Focus: Strategic Considerations for the Road Ahead

Whitepaper Feb 26, 2025

Gene Therapies for Ultra-Rare Diseases: New Partnerships and Business Models

Whitepaper Jan 27, 2025

Oncology Outlook for 2025

Whitepaper Jan 8, 2025

Recommendations for Managing Challenges in Using SEE in HTA Submissions

Whitepaper Jan 6, 2025

China at the Crossroads in Biopharma Innovation: Exportation or Leadership

Whitepaper Dec 12, 2024

Pharma’s AI Dilemma: Balancing Risks and Rewards

Whitepaper Dec 6, 2024

The Cellution to Autoimmunity? The promise and perils of CAR-T

Whitepaper Dec 2, 2024

Navigating Real World Evidence Requirements

Whitepaper Oct 31, 2024

NICE’s Proportional Approach to Technology Appraisals

Whitepaper Aug 5, 2024

Long Follow-Up in Short Supply

Whitepaper Apr 19, 2024

Realize the Full Potential of Your Medical Affairs Team Today by Taking a Holistic Approach to Omnichannel Engagement

1 2 3 4 5 … 7